Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107799
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Viana, Sofia D. | - |
dc.contributor.author | Reis, Flávio | - |
dc.contributor.author | Alves, Rui | - |
dc.date.accessioned | 2023-08-02T10:18:15Z | - |
dc.date.available | 2023-08-02T10:18:15Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1942-0900 | - |
dc.identifier.issn | 1942-0994 | - |
dc.identifier.uri | https://hdl.handle.net/10316/107799 | - |
dc.description.abstract | The mammalian (or mechanistic) target of rapamycin (mTOR) pathway has a key role in the regulation of a variety of biological processes pivotal for cellular life, aging, and death. Impaired activity of mTOR complexes (mTORC1/mTORC2), particularly mTORC1 overactivation, has been implicated in a plethora of age-related disorders, including human renal diseases. Since the discovery of rapamycin (or sirolimus), more than four decades ago, advances in our understanding of how mTOR participates in renal physiological and pathological mechanisms have grown exponentially, due to both preclinical studies in animal models with genetic modification of some mTOR components as well as due to evidence coming from the clinical experience. The main clinical indication of rapamycin is as immunosuppressive therapy for the prevention of allograft rejection, namely, in renal transplantation. However, considering the central participation of mTOR in the pathogenesis of other renal disorders, the use of rapamycin and its analogs meanwhile developed (rapalogues) everolimus and temsirolimus has been viewed as a promising pharmacological strategy. This article critically reviews the use of mTOR inhibitors in renal diseases. Firstly, we briefly overview the mTOR components and signaling as well as the pharmacological armamentarium targeting the mTOR pathway currently available or in the research and development stages. Thereafter, we revisit the mTOR pathway in renal physiology to conclude with the advances, drawbacks, and challenges regarding the use of mTOR inhibitors, in a translational perspective, in four classes of renal diseases: kidney transplantation, polycystic kidney diseases, renal carcinomas, and diabetic nephropathy. | pt |
dc.description.sponsorship | The authors thank HealthyAging 2020 (Centro-01-0145- FEDER-000012) for the Sofia D. Viana post-doc grant (HealthyAging2020 – BID 1.3). This work was financed by the European Regional Development Fund (ERDF) through the Centro 2020 Regional Operational Programme: project CENTRO-01-0145-FEDER-000012-HealthyAging2020 and the COMPETE 2020 - Operational Programme for Competitiveness and Internationalisation and the Portuguese national funds via Fundação para a Ciência e a Tecnologia (FCT), I.P.: project POCI-01-0145-FEDER-007440, as well as by UID/NEU/04539/2013 (CNC.IBILI Consortium strategic project) and POCI-01-0145-FEDER-031712 (project 031712). | pt |
dc.language.iso | eng | pt |
dc.publisher | Hindawi | pt |
dc.relation | info:eu-repo/grantAgreement/UID/NEU/04539/2013 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.title | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges | pt |
dc.type | article | pt |
degois.publication.firstPage | 3693625 | pt |
degois.publication.lastPage | 17 | pt |
degois.publication.title | Oxidative Medicine and Cellular Longevity | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1155/2018/3693625 | - |
degois.publication.volume | 2018 | pt |
dc.date.embargo | 2018-01-01 | * |
dc.identifier.pmid | 30510618 | - |
uc.date.periodoEmbargo | 0 | pt |
dc.identifier.eissn | 1942-0994 | - |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.project.grantno | CNC. IBILI | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-1316-1319 | - |
crisitem.author.orcid | 0000-0003-3401-9554 | - |
crisitem.author.orcid | 0000-0003-3922-3618 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais I&D CIBB - Artigos em Revistas Internacionais I&D ICBR - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Therapeutic-use-of-mTOR-inhibitors-in-renal-diseases-Advances-drawbacks-and-challengesOxidative-Medicine-and-Cellular-Longevity.pdf | 4.26 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
38
checked on Sep 23, 2024
WEB OF SCIENCETM
Citations
31
checked on Sep 2, 2024
Page view(s)
111
checked on Sep 25, 2024
Download(s)
51
checked on Sep 25, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License